Meet our Scientific Advisory Board

The ChromaDex Corp. Scientific Board Members

We are a global bioscience company at the forefront of NAD+ and healthy aging.

The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of nicotinamide adenine dinucleotide (NAD+). A vital coenzyme found in every cell of the human body, NAD+ plays a crucial role in cellular processes, including mitochondrial function, cellular energy production, and DNA repair. NAD+ declines with age and exposure to other everyday stressors, contributing to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor and quality, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside, or NR). Out of all the NAD+ boosters, NR, NMN, and the NAD+ molecule itself, Niagen® NR is the most efficient, safe, and legal NAD+ precursor available.

Food-grade Niagen is the active ingredient in its consumer dietary supplement Tru Niagen®, the number one healthy-aging oral NAD+ supplement in the United States*, available at www.truniagen.com and through partnerships with global retailers and distributors. In 2024, ChromaDex expanded its innovative product portfolio to include Niagen+, pharmaceutical-grade intravenous (IV) and injectable form of Niagen, available exclusively at clinics with a prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. The Company also develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. ChromaDex further offers natural product fine chemicals, known as phytochemicals, and related research and development services.

Key Investment Highlights:

  • Global authority on NAD+ with significant market opportunity across wide-ranging categories ($500B+ TAM in human and pet nutrition, cosmetics and pharmaceuticals)
  • Proven and proprietary NAD+ boosting supplement (Tru Niagen) with $70+ million in sales in 2023 (+52% CAGR (1)) and over $10 million of Niagen ingredient sales in 2023 to food nutrition and supplement companies
  • Strategic partnerships to grow Tru Niagen global distribution footprint with a focus on Asia Pacific
  • Launch of Niagen+ (pharmaceutical-grade IV and injectable Niagen) in 2024, targeting the global intravenous hydration therapy market valued at $2.32 billion globally and $1.15 billion in North America (2022)
  • Independent scientific research supporting the benefits of proprietary ingredients with 30+ published clinical studies and $100MM+ of third-party research
  • Strong intellectual property portfolio with 80+ patents for Niagen and other NAD precursors, including pending patents for intravenous use
  • Strong financial position, with positive $1.9 million Adjusted EBITDA in 2023
  • First company in the U.S. to offer a novel ingredient both as a direct-to-consumer dietary supplement and as an intravenous and injectable pharmaceutical-grade product
(1) *Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Build a Global Brand

In March 2017 ChromaDex began a strategic shift from an ingredient and testing company with the long-term goal of building its new consumer product, TRU NIAGEN®, into a global brand. The company has since expanded retail distribution into four new international markets and has signed supply agreements with strong global partners, including Nestlé Health Science and A.S. Watson Group. (See link to Nestlé Health Science press release) and (See link to latest A.S. Watson Group press release)

Own the Science

As a leader in the growing field of NR and NAD research, ChromaDex continues to build upon and protect its intellectual property, invest in quality research, partner with the world's leading scientists, and educate consumers on the health benefits of NR. (Notable Scientific Research) (Patent Portfolio)

ChromaDex has a strong patent portfolio around TRU NIAGEN®, with over 16 licensed global patents or patents pending. The lead patent is one that is exclusively licensed from Dartmouth. In September 2018, ChromaDex and the Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. (“Elysium”). The complaint alleges that Elysium’s BASIS® dietary supplement violates patents that cover compositions containing isolated nicotinamide riboside (“NR”) held by Dartmouth and licensed exclusively to ChromaDex. (See link to Elysium related litigation)

Focus on Fundamentals

ChromaDex is committed to being a fundamentally sound, principled business operation focused on the long-term. The company continues to build a world class team with greater depth in brand reputation, communications, science, regulatory and sales.

ChromaDex recently secured regulatory approvals from the EU and Australia, which includes five-, and two-year exclusivity, respectively. This continues an unprecedented streak of successful regulatory acceptance of NR, a key point of differentiation from any other novel NAD precursors.

It is the company’s mission to lead by example in this industry. ChromaDex Co-Founder and Chairman, Frank Jaksch, is a Board Member of the Natural Products Association, and ChromaDex Chief Executive Officer, Rob Fried, is a Board Member of the Council for Responsible Nutrition.

For more than 20 years, and through a transition from an ingredients business to a direct-to-consumer dietary supplements company, we have remained true to our commitment to innovation, science and safety.

See What's New...

Latest News

Latest Annual Filings

Latest Quarterly Results

Latest Presentation